SECFilings Executive Interview Series / Christopher Moreau, President & CEO of Miraculins (TSX-V: MOM)
In this segment we will be talking to Mr. Christopher Moreau, President and CEO of Miraculins.
Miraculins is a publicly-traded, Canadian biotechnology company focused on acquiring, developing and commercializing
diagnostic tests and risk assessment technologies for unmet clinical needs. The company’s lead technology programs involve the development
and marketing of non-invasive screening tests to assist in the detection of diabetes and coronary artery disease, and its business
strategy includes the leasing and sale of medical devices and consumables to hospitals, clinics and pharmacies, as well as the
provision of direct-to-public retail testing services, and the delivery of work place health and wellness screenings.
The Scout DS® is a diabetes screening device that uses visible light to fluoresce and detect biomarkers present in the skin associated with prediabetes and type 2 diabetes. Completely non-invasive, the test is done without needles, finger pricking, blood draw or the need to fast… in only 90 seconds.
Diabetes is the fastest growing disease in history. A ‘silent killer’, you can have diabetes for years without any symptoms and the only way to know for sure is to be tested. Fortunately, many of its damaging effects can be prevented or delayed if detected early. The Scout DS® is CE-Marked for the EU, Health
Canada cleared, and the company plans to file pre-submission documentation with the United States Food and Drug Administration (USFDA) regarding the de novoclassification of the Scout DS® as a next step in securing marketing clearance in the United States.
Miraculins is a publicly traded company listed on the Canadian Exchange under ticker symbol MOM and in the US under the symbol MCUIF.